Home > Oncology > ESMO 2019 > Breast Cancer > Triple negative breast cancer gets positive news: KEYNOTE-522 interim results

Triple negative breast cancer gets positive news: KEYNOTE-522 interim results

Presented By
Prof. Peter Schmid, Queen Mary University of London, UK
Conference
ESMO 2019
Trial
Phase 3, KEYNOTE-522

Immunotherapy added to chemotherapy improves pathological complete response in patients with early triple-negative breast cancer, according to late-breaking results from the KEYNOTE-522 trial presented by Prof. Peter Schmid (Queen Mary University of London, UK) [1]. Interim results from the study, which is the first phase 3 trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.

KEYNOTE-522 tested whether adding immunotherapy to chemotherapy prior to surgery could improve pathological complete response and event-free survival in women with early triple-negative breast cancer. A total of 1,174 patients were randomly allocated at a 2:1 ratio to pembrolizumab or placebo, both added to preoperative chemotherapy with anthracyclines, taxanes, and platinum for 5-6 months. After surgery, patients continued their allocated treatment of pembrolizumab or placebo...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on